PRAME, which is expressed in 40% of adult AML patients (Tajeddine et al. 2006), has been shown to be a useful marker for MRD particularly where other tumor specific markers are unavailable (Matsushita et al. 2001; Matsushita et al. 2003). Here, PRAME is linked to acute myeloid leukemia.